Introduction: Esophageal carcinoma is an uncommon malignancy acNumbering for approximately 1% of all malignancies, 6% of all GI malignancies (http://globocan.iarc.fr/factsheets/cancers/ oesophagus.asp). Its distribution across the world is variable. Esophageal cancer is the 8th most common cancer worldwide & 6th leading cause of death world-wide Aim of the study: To determine the outcomes of the definitive management of thoracic esophageal cancer using chemoradiotherapy or radiotherapy, at our institute during the period between 20011 and 2014. Material and Methods: This is a Retrospective study done at our institute from January 2011 and May 2012 patients who received radiotherapy (RT) alone or chemoradiotherapy (CT+RT) for the treatment of carcinoma esophagus. Conclusion: Our study shows that chemoradiotherapy yields significant survival benefit over the radiotherapy alone in the definitive management of patients with T1-3 N0-1 esophageal tumor, who did not undergo surgery. While the overall survival of the entire cohort (N=185) was 13.9 months, chemoradiotherapy offered a survival advantage of 11.6 months over radiotherapy alone (median survival in the CT+RT versus RT alone groups was 19.1 and 7.5 months, respectively). The overall survival rate (OS) at 1 year following treatment was significantly better in the combined chemoradiotherapy group when compared with RT alone group (56% versus 24%).
